Chester County News and Community Website
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), headquartered in Wayne, PA, is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.
WAYNE, PA — Hailed as a leader in kinase discovery and development, Aclaris Therapeutics, Inc. (NASDAQ: ACRS) began 2024 in a robust financial position, charting an ambitious course for the …
Aclaris Therapeutics: A Year of Financial Resilience and Steady Advancements Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a biopharmaceutical company specializing in dermatological treatments, has announced significant changes to its leadership and an impending strategic review of its business …
Aclaris Therapeutics Announces Leadership Shake-up and Strategic Review, Investors Watch Closely Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has released promising top-line results from its Phase 2b study of ATI-1777, a topical “soft” JAK 1/3 inhibitor developed for treating mild …
Aclaris Therapeutics Announces Promising Phase 2b Results for ATI-1777, Boosting Investor Confidence Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is making strategic moves, announcing several updates this week including promising trial results, a shift in drug development focus, and a significant …
Aclaris Therapeutics Advances ATI-1777 into Phase 2b Trial, Plans Workforce Reduction to Preserve Capital Read More WAYNE, PA — Aclaris Therapeutics, Inc., a Pennsylvania-based biopharmaceutical company, announced this week that it has entered into an exclusive patent license agreement with Sun Pharmaceutical Industries, Inc. (Sun Pharma). …
Aclaris Therapeutics and Sun Pharma Sign Exclusive Patent License Agreement for Alopecia Treatment Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) this week announced disappointing top-line results from a Phase 2b study of zunsemetinib (ATI-450) in patients with moderate to severe rheumatoid arthritis …
Aclaris Therapeutics Halts Development of Rheumatoid Arthritis Drug After Phase 2b Study Misses Primary Endpoint Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) this week announced its financial results for the third quarter of 2023 and provided a corporate update.
Aclaris Therapeutics Reports Third Quarter 2023 Financial Results, Provides a Corporate Update Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) this week announced the completion of enrollment into ATI-1777-AD-202, its Phase 2b trial of its investigational topical “soft” Janus kinase (JAK) 1/3 …
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202) Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) recenlty announced positive results from ATI-2138-PKPD-102, a Phase 1 Multiple Ascending Dose (MAD) trial of the investigational compound ATI-2138.
Aclaris Therapeutics Unveils Promising Phase 1 Study of ATI-2138 Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company, this week announced its financial results for the second quarter of 2023 and provided a corporate update.
Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update Read More